Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cyclin D3 is a predictive and prognostic factor in diffuse large B-cell lymphoma.

Martin Filipits1, Ulrich Jaeger, Gudrun Pohl

  • 1Department of Internal Medicine I, Division of Oncology, University of Vienna, A-1090 Vienna, Austria. martin.filipits@akh-wien.ac.at

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|March 16, 2002
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Point-of-care ultrasound tele-didactic teaching for prehospital emergency personnel (POCUS TT study): a randomized non-inferiority trial.

BMC medical education·2026
Same author

Association of surgeon sex with postoperative adverse outcomes in adult cardiac surgery: a nationwide cohort study.

Journal of cardiothoracic surgery·2026
Same author

First attempt success rate of intraosseous access in preterm infants and neonates: a systematic review.

Resuscitation plus·2026
Same author

Long-term prognostic value of ctDNA in early breast cancer: insights from the neoadjuvant ABCSG-34 Trial.

NPJ breast cancer·2026
Same author

Comparative analysis of four PFAS regarding their toxicity to zebrafish development.

Ecotoxicology and environmental safety·2026
Same author

A serious video game for teaching basic point-of-care echocardiography skills: a non-inferiority trial.

BMC medical education·2026

High cyclin D3 expression in diffuse large B-cell lymphoma indicates a poor prognosis. This finding suggests cyclin D3 is a key prognostic factor for patient outcomes in this cancer.

Area of Science:

  • Cell Biology
  • Oncology
  • Hematology

Background:

  • Cyclin D3 regulates cell cycle progression from G1 to S phase.
  • Cyclin D3 expression correlates with proliferation in lymphoid tissues.
  • The prognostic significance of cyclin D3 in non-Hodgkin's lymphomas remains uninvestigated.

Purpose of the Study:

  • To investigate the clinical relevance of cyclin D3 expression in diffuse large B-cell lymphoma (DLBCL).
  • To assess the relationship between cyclin D3 expression and treatment response and survival in DLBCL patients.

Main Methods:

  • Immunohistochemistry was used to evaluate cyclin D3 expression in 81 untreated DLBCL patients.
  • Cyclin D3 expression levels were correlated with clinical stage, extranodal disease, and treatment outcomes.

Related Experiment Videos

  • Multivariate analyses were performed including cyclin D3 and the International Prognostic Index.

    • Main Results:

    • High cyclin D3 expression (>=50%) was associated with advanced clinical stage and multifocal extranodal disease.
    • Patients with high cyclin D3 expression showed significantly lower complete response rates (17% vs 74%) and shorter overall survival (3-year survival 18% vs 74%).
    • Cyclin D3 expression was an independent predictor of response and survival, even when considering the International Prognostic Index.

    Conclusions:

    • Elevated cyclin D3 expression is an independent prognostic factor for poor outcomes in diffuse large B-cell lymphoma.
    • Cyclin D3 serves as a predictive marker for treatment response and overall survival in DLBCL patients.
    • Targeting cyclin D3 may offer therapeutic potential for improving DLBCL patient prognosis.